Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel, Stratified, Multi-center, 12-Week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm)100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI)With the Administration of Placebo or Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent and Adult Patients With Mild to Moderate Asthma
Brief Summary: The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo in adult and adolescent patients with mild to moderate asthma.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate/formoterol fumarate 100/10 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol fumarate 10 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate/formoterol fumarate 100/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone propionate 100; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Formoterol fumarate 10; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate/Formoterol fumarate 250/10 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/Formoterol fumarate 100/10 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 250 | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol fumarate 10 | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate/Formoterol fumarate 250/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: Fluticasone propionate/Formoterol fumarate 100/10; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Fluticasone propionate 250; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Formoterol fumarate 10; Assigned to Arm(s): 4
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate/Formoterol Fumarate 100/10 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate 100 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol fumarate 10 | Intervention Type: DRUG; Name: Fluticasone propionate/Formoterol Fumarate 100/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone propionate 100; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Formoterol fumarate 10; Assigned to Arm(s): 3
D: Arm Label: Fixed Combination of Budesonide and formoterol; Type: EXPERIMENTAL; Interventions: Drug: Fixed combination of budesonide and formoterol | Arm Label: Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Intervention Type: DRUG; Name: Fixed combination of budesonide and formoterol; Assigned to Arm(s): Fixed Combination of Budesonide and formoterol | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide

Answer: A